sometimes value destruction just means underperforming for a long long time $BIIB

I’ll present 'Aleta's novel T cell engager technologies' online, Aug 19, at the Cell Engagers MicroSummit which will blend targeted learning with R&D networking to explore these advanced therapeutics Register here, it's free:  linkedin.com/events/7355949…

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results | Nature Medicine nature.com/articles/s4159…

yer occasional reminder that one of the finest funk bands of the '80s was... youtube.com/watch?v=OOirHv…

Horsewoman on Red Horse #artbots #chagall

No. 3 (Bright Blue, Brown, Dark Blue on Wine) #artbots #rothko

Martha Jungwirth

𝐅𝐫𝐨𝐦 𝐭𝐡𝐞 𝐁𝐚𝐲 𝐀𝐫𝐞𝐚: IDEAYA Biosciences is at the forefront of precision oncology - we discuss the pipeline, including a key pivotal trial that will read out for Darovasertib by the end of the year. $IDYA Full video: biotechtv.com/post/ideaya-bi…

Construction to remove two obsolete dams across PA's Juniata River Water Trail has begun! The removal of these low head dams will reconnect over 156 miles of river and support long-term ecological restoration of the Chesapeake Bay watershed. americanrivers.org/media-item/ame…

must see...

lovely writeup at BBC #Seurat bbc.com/culture/articl…

Christmas Card (Truro's Highland Light) - 1929 #artbots #hopper

🇨🇳 #CTTQ released the first phase 2 clinical trial data of its HER2 bispecific #ADC, #TQB2102, for the treatment of NSCLC. in #WCLC2025 regular abstract. TQB2102 is a HER2 bispecific ADC with a dual-epitope design that enhances drug internalization efficiency and increases

I’m back in Boston and later today will be recording the first episode of ‘Biotech Direct’. This will be BiotechTV’s new regular show featuring a rotating panel of industry experts talking about policy and regulatory topics in the news. Will likely post sometime tomorrow.

🇨🇳 #GenFleet Therapeutics announced that the latest clinical trial data for its small-molecule KRAS G12D inhibitor, #GFH375, as a monotherapy for NSCLC patients has been selected for #WCLC2025 LBA and a mini-oral presentation. The Phase 1/2 study demonstrated that GFH375 has an

'Heat Wave' seems likely to become an antiquated weather term in New England ... like 'Indian Summer' and 'January Thaw'

smart list

Paul D. Rennert From earlier, via Madeleine Armstrong oncologypipeline.com/apexonco/systi…